



Arvinas (New Haven, CT, USA) has named **Angela Shen** (left) chief medical officer. She brings extensive experience in clinical development, medical affairs and business development to the company, having most recently served as a global clinical program head at Novartis Oncology. She was previously head of clinical evaluation for Novartis' oncology business development group and a clinical lead for drug development at Exelixis.

"Angela has been at the cutting edge of drug development, in uncharted territories," said Tim Shannon, general partner at Canaan Partners and chairman of Arvinas' board of directors. "Angela's unique expertise and clinical perspectives will help drive the vision we have of developing Arvinas' innovative platform into a new clinical paradigm."

Cancer immunotherapy developer Medigene (Martinsried/Munich, Germany) has announced that CFO **Peter Llewellyn-Davies** has left the company to pursue new business challenges.

Sanofi (Paris) has named **Ameet Nathwani** executive vice president, group chief medical officer, a position was previously held by **Paul Chew** who plans to retire later this year. Nathwani was previously senior vice president and global head of medical affairs at Novartis.

Simon Allen has been appointed CEO of mitochondria-based therapeutics developer CohBar (Menlo Park, CA, USA). He brings more than 20 years of industry experience, having previously served as a consultant to Solstice Biologics and chief business officer of Ambrox.

CRISPR Therapeutics (Basel, Switzerland and Cambridge, MA, USA) has named **Marc Becker** CFO. Becker brings over 20 years of experience in commercial, operational and corporate finance. He was most recently CFO and senior vice president of rEVO Biologics.

Hemispherx Biopharma (Philadelphia) has announced several changes to its executive management team in light of the termination of longtime chairman and CEO **William Carter**. **William M. Mitchell** has been elected chairman of the board. An independent director since July 1998, Mitchell is professor of pathology, microbiology and immunology at Vanderbilt University School of Medicine and is a board-certified physician. **David R. Strayer**, the company's medical director since 1986, has been named CSO. Finally, **Adam Pascale** has been named CFO in addition to his current responsibilities as chief accounting officer. Pascale joined Hemispherx in 1998.

Kymab (Cambridge, UK) has announced the appointment of **David Chiswell OBE** as CEO. Chiswell has served as interim CEO since early 2015. He will step down from his role as chairman and **Tim Rink** will take the role of lead director.

Provista Diagnostics (New York) has named **Susan Gross** as chief medical officer. Gross is

a professor of clinical obstetrics & gynecology and women's health, pediatrics and genetics at the Albert Einstein College of Medicine. She joins Provista from Natera, where she served as chief medical officer, overseeing the development of the company's prenatal screening tests.



Andrew Howden (left) has been named an independent nonexecutive director of ASLAN Pharmaceuticals (Singapore). Howden has almost 35 years

of global pharma industry experience, most recently as CEO of iNova Pharmaceuticals until its acquisition by Valeant Pharmaceuticals. Previously, he served as president of IMS Health's Asia Pacific region, regional vice president Asia Pacific at AstraZeneca, and held senior roles at Quintiles in Europe and Asia.

Arrogene (Los Angeles) has announced the appointment of **Jack Kavanaugh** as executive chairman. He previously served as founder, chairman and CEO of ZetaRX, the core of Juno Therapeutics.

Erik Kinnman has been appointed CEO of NeuroVive Pharmaceutical (Lund, Sweden), succeeding interim CEO **Jan Nilsson**, who will resume his position as COO. Kinnman has held a number of senior leadership positions in biopharma companies including AstraZeneca and Sobi, and was most recently CEO and chief medical officer of his own business consultancy.



C4 Therapeutics (Cambridge, MA, USA) has announced the appointment of **Thomas E. Needham, Jr.** (left) as chief business officer. Needham has over 20 years of experience in venture

capital, business development, corporate strategy and executive management, most recently serving as managing director at Synthesis Capital. Previously, he was a principal at private equity firm Advent International and vice president of business development at GPC Biotech and Mitotix.

Protagonist Therapeutics (Milpitas, CA, USA) has appointed **Thomas P. O'Neil** as CFO. O'Neil previously held the same position at agbiotech firm Arcadia Biosciences.

Geoff Smith has been appointed CEO of Cambridge Epigenetix (Cambridge, UK). He joins from Illumina, where he served most recently as site lead and vice president of product development. Also, in conjunction with the close of a \$21-million series B financing led by GV (formerly Google Ventures), **Tom Hulme**, general partner of GV, will join the Cambridge Epigenetix board and co-founder **Bobby Yerramilli-Rao** will assume the role of chairman.

GlaxoSmithKline (Middlesex, UK) has announced that its CEO, **Sir Andrew Witty**, will retire from the company in March 2017. GSK's board of directors will conduct a formal search for a successor and will consider internal and external candidates for the role.